A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study. This is an ASCO Meeting Abstract from the 2013 ...
A four-condition crossover design (hydromorphone, dronabinol, combination, placebo) in 21 participants showed no additive or ...
Effect of weight loss on survival in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy and surgery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results